Dade sells urinalysis tests to Quidel:
This article was originally published in Clinica
Executive Summary
US point-of-care diagnostics company Quidel has completed the acquisition of Dade Behring's Rapignost urine test strip business. "Urinalysis tests are important tools for the physician's overall assessment of patient health and will complement Quidel's existing point-of-care business," said the San Diego, California-based company's vice-chairman, president and CEO, Andre de Bruin. "The addition of this product line is expected to contribute to our near-term revenue and profit growth because it can be included within our existing sales and distribution structure." Financial details were not disclosed.